Cojean, S.
Publications
P300
RSC Med. Chem. 2025, 16, 3746–3763.
Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy
https://doi.org/10.1039/D5MD00257E
P290
ChemMedChem. 2025, 20, e202400862.
Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.
https://doi.org/10.1002/cmdc.202400862
P287
Eur. J. Med. Chem. Rep. 2024, 12, 100228.
Biological properties and in silico studies of thiazolopyrimidine derivatives active against visceral and cutaneous Leishmania spp. amastigote forms.
https://doi.org/10.1016/j.ejmcr.2024.100228.
P269
Nat. Prod. Res. 2023
Phytochemical, antileishmanial, antifungal and cytotoxic profiles of Thymelaea tartonraira (L.) All. extracts.
https://doi.org/10.1080/14786419.2023.2252153
P238
Med. Chem. Lett. 2021, 47, 128196.
Anti-protozoal and anti-fungal evaluation of 3,5-disubstituted 1,2-dioxolanes. Bioorg.
doi: 10.1016/j.bmcl.2021.128196
P231
Eur. J. Med. Chem. 2021, 210, 112956.
In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.
doi: 10.1016/j.ejmech.2020.112956
Autres publications scientifiques
Brevets
Thèse